Characterization of genetic variants of GIPR reveals a contribution of β-arrestin to metabolic phenotypes

Incretin-based therapies are highly successful in combatting obesity and type 2 diabetes 1 . Yet both activation and inhibition of the glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) in combination with glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) activation have resulted in...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	NATURE METABOLISM 2024, Vol.6 (7), p.1268-1281
Hauptverfasser:	Kizilkaya, Hüsün S., Sørensen, Kimmie V., Madsen, Jakob S., Lindquist, Peter, Douros, Jonathan D., Bork-Jensen, Jette, Berghella, Alessandro, Gerlach, Peter A., Gasbjerg, Lærke S., Mokrosiński, Jacek, Mowery, Stephanie A., Knerr, Patrick J., Finan, Brian, Campbell, Jonathan E., D’Alessio, David A., Perez-Tilve, Diego, Faas, Felix, Mathiasen, Signe, Rungby, Jørgen, Sørensen, Henrik T., Vaag, Allan, Nielsen, Jens S., Holm, Jens-Christian, Lauenborg, Jeannet, Damm, Peter, Pedersen, Oluf, Linneberg, Allan, Hartmann, Bolette, Holst, Jens J., Hansen, Torben, Wright, Shane C., Lauschke, Volker M., Grarup, Niels, Hauser, Alexander S., Rosenkilde, Mette M.
Format:	Artikel
Sprache:	eng
Schlagworte:	631/208/191 631/443/319 692/163/2743 692/163/2743/393 Biomedical and Life Sciences Clinical Medicine Endocrinology and Diabetes Endokrinologi och diabetes Klinisk medicin Letter Life Sciences Medical and Health Sciences Medicin och hälsovetenskap
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!